STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the second quarter 2022. “CHMPs recommendation to grant Pepaxti a ... read more

Oslo, Norway, 11 August 2022 – Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2022 results on Thursday 18 August 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. The results report ... read more

PHILADELPHIA, PA., AUGUST 10, 2022 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ABX1100, an investigational Centyrin-siRNA conjug... read more

Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Business Operations Expansion of Tildacerfont Patent Portfolio Estate with Key Method of Use Patents ... read more

FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administration dosing regimen in Phase 1 study of FPI-1434 presented at SNMMI 2022 Annual Meeting Company strengthens actiniu... read more